Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1-images in multiple sclerosis.
The influence of HLA-DRB1*15 on motor cortical pathology in multiple sclerosis.
Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis.
Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.
Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.
Cancer risk in multiple sclerosis: findings from British Columbia, Canada.
Association between Change in Normal Appearing White Matter Metabolites and Intrathecal Inflammation in Natalizumab-Treated Multiple Sclerosis.
Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
Low-contrast visual tests reveal better alemtuzumab efficacy
The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia.
"Tell me what you want, what you really really want….": asking people with multiple sclerosis about enhancing their participation in physical activity.
Active Biotech announce that European Medicines Agency accepts start of scientific review of the marketing authorization application for laquinimod in relapsing-remitting multiple sclerosis
The environment and disease: association or causation?
Evaluation of sexual function in women at two stages of multiple sclerosis.
Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination.
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.
Validity and Reliability of a Persian Translation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS).
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis.
Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.
The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis.
Early activation of CD4+ and CD8+ T lymphocytes by myelin basic protein in subjects with MS.

Pages